Peter Michael Bruno, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Naphthyridines | 1 | 2020 | 121 | 0.690 |
Why?
|
Benzothiazoles | 1 | 2020 | 250 | 0.670 |
Why?
|
Organoplatinum Compounds | 2 | 2017 | 409 | 0.650 |
Why?
|
Cysteine | 1 | 2023 | 870 | 0.630 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2023 | 1359 | 0.560 |
Why?
|
Antineoplastic Agents | 13 | 2020 | 13635 | 0.490 |
Why?
|
Cisplatin | 2 | 2017 | 1617 | 0.490 |
Why?
|
Coordination Complexes | 4 | 2017 | 118 | 0.470 |
Why?
|
Carboplatin | 1 | 2017 | 800 | 0.470 |
Why?
|
Ribosomes | 1 | 2017 | 499 | 0.460 |
Why?
|
Phenanthrolines | 3 | 2017 | 59 | 0.400 |
Why?
|
Neoplastic Stem Cells | 5 | 2017 | 1380 | 0.390 |
Why?
|
Cell Survival | 2 | 2020 | 5877 | 0.370 |
Why?
|
Osmium | 2 | 2014 | 21 | 0.250 |
Why?
|
Copper | 2 | 2016 | 368 | 0.230 |
Why?
|
Organometallic Compounds | 2 | 2016 | 667 | 0.200 |
Why?
|
Doxorubicin | 2 | 2020 | 2218 | 0.200 |
Why?
|
Xenograft Model Antitumor Assays | 3 | 2017 | 3562 | 0.190 |
Why?
|
Cell Line, Tumor | 9 | 2020 | 16646 | 0.180 |
Why?
|
Lymphoma | 2 | 2020 | 1873 | 0.180 |
Why?
|
DNA Topoisomerases, Type II | 1 | 2020 | 121 | 0.170 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2023 | 877 | 0.160 |
Why?
|
Thiocarbamates | 1 | 2017 | 32 | 0.160 |
Why?
|
Phenanthridines | 1 | 2017 | 52 | 0.150 |
Why?
|
Ligands | 2 | 2023 | 3311 | 0.150 |
Why?
|
Nanoparticles | 3 | 2017 | 1906 | 0.150 |
Why?
|
RNA Interference | 4 | 2020 | 2899 | 0.140 |
Why?
|
Nickel | 1 | 2017 | 129 | 0.140 |
Why?
|
Platinum Compounds | 1 | 2017 | 97 | 0.140 |
Why?
|
Cobalt | 1 | 2016 | 159 | 0.140 |
Why?
|
Sphingolipids | 1 | 2017 | 160 | 0.140 |
Why?
|
Principal Component Analysis | 2 | 2017 | 937 | 0.140 |
Why?
|
Naproxen | 1 | 2016 | 100 | 0.140 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 2 | 2016 | 2277 | 0.140 |
Why?
|
Leukemia, Experimental | 1 | 2016 | 247 | 0.140 |
Why?
|
Rhenium | 1 | 2015 | 14 | 0.130 |
Why?
|
Nitrogen Compounds | 1 | 2014 | 7 | 0.130 |
Why?
|
Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2015 | 109 | 0.130 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2020 | 1213 | 0.130 |
Why?
|
DNA Damage | 4 | 2017 | 2419 | 0.120 |
Why?
|
Cyclooxygenase 2 Inhibitors | 1 | 2016 | 320 | 0.120 |
Why?
|
2,2'-Dipyridyl | 1 | 2013 | 12 | 0.120 |
Why?
|
Aneuploidy | 1 | 2017 | 533 | 0.120 |
Why?
|
Endonucleases | 1 | 2016 | 383 | 0.110 |
Why?
|
Genetic Techniques | 1 | 2016 | 436 | 0.110 |
Why?
|
Camptothecin | 1 | 2016 | 570 | 0.110 |
Why?
|
Apoptosis | 4 | 2017 | 9714 | 0.110 |
Why?
|
Drug Synergism | 2 | 2017 | 1792 | 0.110 |
Why?
|
Gene Expression Regulation, Leukemic | 1 | 2016 | 649 | 0.110 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2020 | 10945 | 0.100 |
Why?
|
Embryo, Mammalian | 1 | 2017 | 1698 | 0.100 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2020 | 8400 | 0.090 |
Why?
|
Peptides | 1 | 2023 | 4395 | 0.090 |
Why?
|
Immunoconjugates | 1 | 2017 | 889 | 0.090 |
Why?
|
Neoplasms | 2 | 2017 | 21507 | 0.090 |
Why?
|
Protein Binding | 1 | 2023 | 9375 | 0.090 |
Why?
|
Molecular Conformation | 3 | 2016 | 565 | 0.090 |
Why?
|
Ovarian Neoplasms | 2 | 2017 | 4815 | 0.090 |
Why?
|
Tumor Suppressor Protein p53 | 3 | 2016 | 2948 | 0.090 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2017 | 4743 | 0.090 |
Why?
|
Stress, Physiological | 1 | 2017 | 1405 | 0.090 |
Why?
|
Blotting, Western | 1 | 2017 | 5181 | 0.080 |
Why?
|
Drug Screening Assays, Antitumor | 3 | 2016 | 740 | 0.080 |
Why?
|
RNA, Small Interfering | 1 | 2017 | 3498 | 0.080 |
Why?
|
Drug Combinations | 1 | 2012 | 1959 | 0.080 |
Why?
|
Drug Design | 1 | 2012 | 1088 | 0.070 |
Why?
|
Fibroblasts | 1 | 2017 | 4137 | 0.070 |
Why?
|
Homeostasis | 1 | 2017 | 3348 | 0.070 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2017 | 5148 | 0.070 |
Why?
|
Structure-Activity Relationship | 3 | 2016 | 3146 | 0.060 |
Why?
|
Sensitivity and Specificity | 1 | 2020 | 14740 | 0.060 |
Why?
|
Breast Neoplasms | 3 | 2016 | 20676 | 0.060 |
Why?
|
Cyclooxygenase 2 | 2 | 2016 | 612 | 0.060 |
Why?
|
Bacterial Proteins | 1 | 2016 | 3866 | 0.050 |
Why?
|
Necrosis | 2 | 2017 | 1643 | 0.050 |
Why?
|
Mice, Nude | 2 | 2017 | 3692 | 0.050 |
Why?
|
Mice | 6 | 2017 | 81002 | 0.050 |
Why?
|
Immunotherapy | 1 | 2015 | 4391 | 0.050 |
Why?
|
Reactive Oxygen Species | 2 | 2017 | 2084 | 0.040 |
Why?
|
Sphingosine N-Acyltransferase | 1 | 2017 | 8 | 0.040 |
Why?
|
Colorectal Neoplasms | 1 | 2017 | 6726 | 0.040 |
Why?
|
Glucosyltransferases | 1 | 2017 | 100 | 0.040 |
Why?
|
Animals | 7 | 2017 | 168368 | 0.040 |
Why?
|
Genetic Variation | 1 | 2012 | 6539 | 0.040 |
Why?
|
Gene Expression Profiling | 1 | 2013 | 9387 | 0.040 |
Why?
|
Ceramides | 1 | 2017 | 199 | 0.030 |
Why?
|
Models, Biological | 1 | 2013 | 9609 | 0.030 |
Why?
|
Cell Proliferation | 3 | 2017 | 10455 | 0.030 |
Why?
|
Cyclooxygenase 1 | 1 | 2016 | 105 | 0.030 |
Why?
|
Humans | 14 | 2020 | 739398 | 0.030 |
Why?
|
DNA Modification Methylases | 1 | 2016 | 206 | 0.030 |
Why?
|
Polyesters | 1 | 2016 | 367 | 0.030 |
Why?
|
Drug Stability | 1 | 2015 | 292 | 0.030 |
Why?
|
Prodrugs | 1 | 2016 | 271 | 0.030 |
Why?
|
DNA Repair Enzymes | 1 | 2016 | 348 | 0.030 |
Why?
|
Morpholines | 1 | 2017 | 562 | 0.030 |
Why?
|
Receptor, PAR-1 | 1 | 2015 | 114 | 0.030 |
Why?
|
Dacarbazine | 1 | 2016 | 568 | 0.030 |
Why?
|
Drug Carriers | 1 | 2016 | 693 | 0.030 |
Why?
|
Molecular Structure | 1 | 2016 | 1925 | 0.030 |
Why?
|
Neoplasms, Experimental | 1 | 2016 | 1280 | 0.020 |
Why?
|
Polyethylene Glycols | 1 | 2016 | 1182 | 0.020 |
Why?
|
Systems Biology | 1 | 2012 | 471 | 0.020 |
Why?
|
Mice, Inbred BALB C | 1 | 2017 | 6397 | 0.020 |
Why?
|
Sequence Analysis, RNA | 1 | 2016 | 1994 | 0.020 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2017 | 1849 | 0.020 |
Why?
|
Cell Cycle | 1 | 2015 | 2960 | 0.020 |
Why?
|
Tumor Suppressor Proteins | 1 | 2016 | 2845 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2013 | 2711 | 0.020 |
Why?
|
Drug Delivery Systems | 1 | 2016 | 2220 | 0.020 |
Why?
|
Carcinoma | 1 | 2016 | 2361 | 0.020 |
Why?
|
Survival Analysis | 1 | 2017 | 10247 | 0.020 |
Why?
|
Models, Molecular | 1 | 2015 | 5460 | 0.020 |
Why?
|
Cell Line | 1 | 2016 | 15987 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2017 | 19220 | 0.010 |
Why?
|
Female | 5 | 2017 | 378853 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2017 | 21863 | 0.010 |
Why?
|
Algorithms | 1 | 2013 | 13872 | 0.010 |
Why?
|
Treatment Outcome | 1 | 2017 | 62693 | 0.010 |
Why?
|
Signal Transduction | 1 | 2013 | 23355 | 0.010 |
Why?
|
Male | 1 | 2017 | 349022 | 0.000 |
Why?
|